AUROPHARMA2021-10-012021-12-31in-bse-fin:OneOperatingExpenses01Member AUROPHARMA2021-10-012021-12-31in-bse-fin:FourOperatingExpenses01Member AUROPHARMA2021-10-012021-12-31in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member AUROPHARMA2021-10-012021-12-31in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss02Member AUROPHARMA2021-10-012021-12-31in-bse-fin:FourItemsThatWillNotBeReclassifiedToProfitAndLoss01Member AUROPHARMA2021-10-012021-12-31in-bse-fin:FourItemsThatWillNotBeReclassifiedToProfitAndLoss02Member AUROPHARMA2021-10-012021-12-31in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss01Member AUROPHARMA2021-10-012021-12-31in-bse-fin:FourItemsThatWillBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares AUROPHARMA 2021-04-01 2022-03-31 2022-01-31 INR Lakhs Third quarter Single segment Pharmaceutical Products 2021-10-01 2021-12-31 Unaudited Consolidated 60022200000.00 649900000.00 60672100000.00 18325200000.00 6501600000.00 2615600000.00 8689100000.00 161300000.00 2990500000.00 13728000000.00 53011300000.00 7660800000.00 347900000.00 8008700000.00 2476000000.00 -581100000.00 1894900000.00 0.00 6113800000.00 0.00 0.00 0.00 -70900000.00 6042900000.00 -581800000.00 5461100000.00 5465500000.00 -4400000.00 6047300000.00 -4400000.00 585900000.00 1 10.32 10.32 0.00 0.00 10.32 10.32 1. The financial results of the Group have been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013, read with the relevant rules issued thereunder. 2. The above consolidated financial results have been prepared in accordance with principles and procedures as set out in the Ind AS 110 on Consolidated financial statements and Ind AS 28 on Investments in Associates and Joint ventures notified under Section 133 of Companies Act, 2013 and Companies (Indian Accounting Standards) Rules, 2015, as amended. 3. The above consolidated financial results as reviewed by the audit committee have been approved by the Board of Directors at its meeting held on 09 February 2022. The statutory auditors have carried out limited review of the above results for quarter and nine months ended 31 December 2021. An unmodified report has been issued by them thereon. 4. Profit before tax includes exceptional items of Rs.3,479 lakhs for the quarter ended 31 December 2021 which consists of: a. Rs. 11,567 lakhs gain on sale and lease back of Group’s real estate property situated in Dayton, New Jersey. b. Rs. 8,088 lakhs impairment charge towards certain product related intangibles considering the de-prioritization / discontinuation of further development. Profit before tax includes exceptional items of Rs.281,458 lakhs for the year ended 31 March 2021 which consists of: a. Rs. 309,665 lakhs gain on disposal of business assets of a wholly-owned step-down subsidiary, Natrol LLC, United States of America. Pursuant to the Board’s approval on 25 October 2020, the Group had entered into a definitive agreement to dispose of business assets of Natrol LLC, as a going concern with related assets, liabilities, products, brands and employees for a cash price of USD 550 million. b. Rs. 15,285 lakhs gain on account of remeasurement of equity interest in Eugia Pharma Specialties Limited, a joint venture company as at 6 November 2020. The Board in its meeting held on 16 October 2020 had decided to enter into a share purchase agreement to acquire 100% equity share capital of MViyes Pharma Ventures Private Limited. MViyes is holding 29.13% shareholding in Eugia Pharma Specialties Limited, a joint venture company in which the Parent Company, through its wholly-owned subsidiary company, is holding 70.87%. By this acquisition, both Eugia Pharma Specialties Limited and MViyes Pharma Ventures Private Limited had become wholly owned subsidiaries. c. Rs. 43,492 lakhs impairment charges taken considering the difficult economic conditions and the continued impact of Covid 19 in certain markets towards product related intangibles and goodwill. Tax expenses on the above exceptional item is Rs. 70,489 lakhs. Profit after tax excluding exceptional item (net of tax) for the year ended 31 March 2021 is Rs. 322,414 lakhs. 5. The Group operates in only one segment viz., 'Pharmaceutical Products'. Single segment 2021-04-01 2021-12-31 Unaudited Consolidated 176461200000.00 2714700000.00 179175900000.00 54674100000.00 14686900000.00 6799800000.00 25976900000.00 394300000.00 8729500000.00 40199800000.00 151461300000.00 27714600000.00 347900000.00 28062500000.00 7085200000.00 -3800000.00 7081400000.00 0.00 20981100000.00 0.00 0.00 0.00 -271400000.00 20709700000.00 510200000.00 21219900000.00 21227100000.00 -7200000.00 20716900000.00 -7200000.00 585900000.00 1 35.36 35.36 0.00 0.00 35.36 35.36 Other Expenses 13728000000.00 Other Expenses 40199800000.00 6. 'During the quarter, the following companies have been incorporated/acquired/liquidated: Eugia (UK) Limited - incorporated w.e..f 21 October, 2021 CuraTeQ Biologics GmbH - Liquidated w.e.f. 7 October, 2021 Eugia Pharma (Malta) Limited, Malta incorporated w.e.f. 14 October, 2021 Aurobindo Pharma Gmbh Germany (merged with Puren Pharma GmbH w.e.f. 1 October, 2021) Eugia Pharma (Australia) PTY Limited incorporated w.e.f.15 December, 2021 Eugia Pharma INC, Canada incorporated w.e.f. 29 October, 2021 Eugia Pharma Industria Farmaceutica Limitada incorporated w.e.f. 20 December, 2021 Auro vaccines Private Limited incorporated w.e.f. 8 November, 2021 During the quarter, the Group has acquired membership rights in Mylan LLC, Puerto Rico w.e.f 30 December 2021 pursuant to a purchase agreement with Mylan International Holdings Inc. This acquisition is not material to the Group. 7. As at 31 December 2021, the Holding Company has not elected to apply tax rate prescribed under Section 115BAA of the Income tax Act, 1961 and accordingly continue to account for income taxes under old tax rate. 8.The Group continues to monitor the possible effects that may result from the pandemic relating to COVID-19. The Group continues to take several business continuity measures with a view to ensure minimal disruption with respect to operations including production and distribution activities. While the Group has experienced certain challenges in certain markets, where the impact of the pandemic is prolonged and business environment is impacted due to the uncertainty, the Group has not experienced any significant difficulties with respect to market demand, financing capital expansion projects, collections or liquidity in other markets. Based on internal and external sources of information, current economic environment and future economic indicators, Group has assessed the financial impact of the COVID-19 situation on its operations particularly on the carrying amounts of receivables, inventories, property, plant and equipment, goodwill and other intangible assets. Wherever considered necessary an assessment of the impact has been carried out and the impact if material on account of impairment have been recorded. However, the impact of the pandemic could be different from those estimated today considering the uncertainties involved. The Group will continue to monitor any material changes to future economic conditions. 9.The Board has approved interim dividend @150% i.e.Re.1.50 (Rupee one and fifty paisa only) per equity share of Re.1/- (Rupee one only) for the year 2021-22.